LOG IN
SIGN UP
MARKET
AVXL
AVXL
Anavex Life Scie
NASDAQ
Real-time Quotes | Nasdaq Last Sale
9.70
+0.64
+7.01%
Opening 14:59 05/27 EDT
OPEN
9.10
PREV CLOSE
9.06
HIGH
9.73
LOW
8.84
VOLUME
578.27K
TURNOVER
3.12M
52 WEEK HIGH
31.50
52 WEEK LOW
7.13
MARKET CAP
750.48M
P/E (TTM)
-16.7473
1D
5D
1M
3M
1Y
5Y
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions migh...
Zacks · 2d ago
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmenta...
GlobeNewswire · 05/19 11:00
Here's why meme stocks are hinting at another flashy rally for `junk stocks`
We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.
Yahoo Finance · 05/13 20:17
Anavex Life Sciences GAAP EPS of -$0.14 beats by $0.03
Anavex Life Sciences press release (NASDAQ:AVXL): Q1 GAAP EPS of -$0.14 beats by $0.03. Cash and cash equivalents of $153.3 million on March 31, 2022, compared to $152.1 million at
Seekingalpha · 05/10 11:11
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ETNEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated th...
GlobeNewswire · 05/03 11:00
Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett SyndromeNEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (N...
GlobeNewswire · 04/27 11:00
EXPI, AVXL and IXHL among after hour movers
Gainers: Enphase Energy (ENPH) +5%. eXp World Holdings (EXPI) +5%. Lucid Group (LCID) +5%. Anavex Life Sciences (AVXL) +5%. Wejo Group Limited (WEJO) +5%. Losers: Incannex Healthcare (IXHL) -14%. Sono Group (SEV) -12%. F5 (FFIV) -11%.
Seekingalpha · 04/26 21:50
No Data
Learn about the latest financial forecast of AVXL. Analyze the recent business situations of Anavex Life Scie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 5 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AVXL stock price target is 33.60 with a high estimate of 42.00 and a low estimate of 16.00.
Current 9.71
EPS
Actual
Estimate
-0.14-0.10-0.07-0.03
Institutional Holdings
Institutions: 161
Institutional Holdings: 29.66M
% Owned: 38.31%
Shares Outstanding: 77.41M
TypeInstitutionsShares
Increased
52
3.77M
New
20
510.80K
Decreased
29
1.12M
Sold Out
31
435.14K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/President/Chief Executive Officer/Secretary/Director
Christopher Missling
Chief Financial Officer/Treasurer
Sandra Boenisch
Lead Director/Independent Director
Claus van der Velden
Independent Director
Peter Donhauser
Independent Director
Jiong Ma
Independent Director
Athanasios Skarpelos
Independent Director
Steffen Thomas
No Data
No Data
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.
Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.